Broken String Biosciences

Broken String Biosciences is a biotechnology company that provides a platform for genome-wide on- and off-target analysis to support the development of safe gene editing therapies. Its core technology, INDUCE-seq, is an NGS-based platform that directly labels and captures DNA breaks in cells, allowing researchers to measure and quantify editing specificity at single-nucleotide resolution. By utilizing a PCR-free workflow, the company's BreakMap platform enables scientists to map and characterize DNA breaks across diverse cell types—including primary, stem, and immortalized cells—without relying on indirect or fragmented legacy assays. This solution provides a standardized, unified workflow that integrates wet-lab sample preparation with a cloud-based bioinformatics platform to translate raw sequencing data into clear, ranked, and actionable insights.

The company's offerings are designed to help therapy developers navigate the complexities of gene editing research, from early discovery through to IND-enabling studies. By providing empirical, genome-wide data, Broken String Biosciences helps partners reduce program risk, optimize guide RNA performance, and meet increasing regulatory expectations for safety assessments. Headquartered in the United Kingdom, the company collaborates with gene editing organizations globally, offering in-house control over critical safety data and helping to accelerate the path toward clinical applications for genetic medicines. Their work is supported by significant venture funding and an executive leadership team focused on commercial and scientific expansion in the biotechnology sector.